Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 26, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 300,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,203.91 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,218,795,776 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 300,000 repurchased shares. Consequently, the total number of shares in issue remains 5,218,795,776, while the Treasury holding stands at 474,194,158 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (300,000 shares at 1,203.91 pence) against the company's cash position in broader financial reports.
- Confirm the updated Treasury share count of 474,194,158 and its impact on the 9.09% voting rights calculation.
- Note that the 5,218,795,776 shares in issue is the correct denominator for shareholder notification thresholds under Disclosure and Transparency Rules.